There is already evidence that overexpression of RPS6KA1—independently or in the context of FLT3-ITD mutation—is associated with worse prognosis, poor survival rates, and chemoresistance of AML patients [47]. Here, RPS6KA1 is linked to acute myeloid leukemia.